

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6013742

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	THOMAS LINES	12/28/2015
	QUERCEGEN PHARMA LLC	12/28/2015
	QUERCEGEN PHARMA LLP	12/28/2015
	QUERCEGEN TECHNOLOGIES	12/28/2015
	QUERCEGEN PHARMACEUTICALS, LLC	12/28/2015
	QUERCEGEN HOLDINGS, LLC	12/28/2015
	NEW SUN NUTRITION, LLC	12/28/2015
	THE FRS COMPANY	12/28/2015
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	QUERCEGEN PHARMA, AG.	
<b>Street Address:</b>	BUELSTRASSE 1	
<b>City:</b>	OBERWIL-LIELI	
<b>State/Country:</b>	SWITZERLAND	
<b>Postal Code:</b>	8966	
<b>PROPERTY NUMBERS Total: 26</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Patent Number:</b>	7745486	
<b>Patent Number:</b>	8440704	
<b>Patent Number:</b>	7745487	
<b>Patent Number:</b>	8901109	
<b>Patent Number:</b>	8507548	
<b>Patent Number:</b>	8044096	
<b>Patent Number:</b>	8202900	
<b>Patent Number:</b>	7811568	
<b>Patent Number:</b>	8546342	
<b>Application Number:</b>	11364136	
<b>Patent Number:</b>	8574619	
<b>Patent Number:</b>	8680053	
<b>Application Number:</b>	13729544	

PATENT

Property Type	Number
Patent Number:	10391096
Application Number:	13303467
Application Number:	16511620
Application Number:	62014488
Application Number:	14744662
Application Number:	13350266
Patent Number:	6821536
Application Number:	10692178
Patent Number:	7270840
Patent Number:	7569239
Patent Number:	8318224
Patent Number:	8318225
Application Number:	13679704

#### CORRESPONDENCE DATA

##### Fax Number:

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Email: docket@c-m.com

Correspondent Name: CESARI AND MCKENNA, LLP

Address Line 1: ONE LIBERTY SQUARE

Address Line 4: BOSTON, MASSACHUSETTS 02109

ATTORNEY DOCKET NUMBER: 218017-0000

NAME OF SUBMITTER: RUSSELL L. WIDOM, PH.D.

SIGNATURE: /Russell L. Widom/

DATE SIGNED: 03/13/2020

#### Total Attachments: 17

source=2DI5263#page1.tif  
source=2DI5263#page2.tif  
source=2DI5263#page3.tif  
source=2DI5263#page4.tif  
source=2DI5263#page5.tif  
source=2DI5263#page6.tif  
source=2DI5263#page7.tif  
source=2DI5263#page8.tif  
source=2DI5263#page9.tif  
source=2DI5263#page10.tif  
source=2DI5263#page11.tif  
source=2DI5263#page12.tif  
source=2DI5263#page13.tif  
source=2DI5263#page14.tif

source=2DI5263#page15.tif

source=2DI5263#page16.tif

source=2DI5263#page17.tif

## ASSIGNMENT

THIS ASSIGNMENT is made effective as of 28<sup>th</sup> day of December, 2015.

WHEREAS, the following entities (collectively referred to as "Assignors") are the assignees of certain inventions as set forth in the identified exhibits (hereinafter referred to as "PATENT PROPERTY"). The Assignors are as follows:

1. Thomas Lines, a citizen of South Africa, residing at 4 Ellen Mary Lane, Wayland, MA 01778 is the assignee of certain inventions as set forth in Exhibit A;
2. Quercegen Pharma LLC, having a business address at 275 Grove Street, Suite 2-400, Newton, MA 02466, is the assignee of certain inventions as set forth in Exhibit B;
3. Quercegen Pharma LLP, having a business address at 275 Grove Street, Suite 2-400, Newton, MA 02466, is the assignee of certain inventions as set forth in Exhibit C;
4. Quercegen Technologies, having a business address at 275 Grove Street, Suite 2-400, Newton, MA 02466, is the assignee of certain inventions as set forth in Exhibit D;
5. Quercegen Pharmaceuticals, LLC, having a business address at 225 Cedar Hill Street, Suite 200, Marlborough, MA 01752, is the assignee of certain inventions as set forth in Exhibit E;
6. Quercegen Holdings, LLC, having a business address at 51 Locust Avenue, New Canaan, CT 06840 is the assignee of certain inventions as set forth in Exhibit F;
7. New Sun Nutrition , LLC having a business address at 197 Wood Street, Lexington, MA 02421 is the assignee of certain inventions as set forth in Exhibit G; and
8. The FRS Company having a business address at 101 Lincoln Centre Drive, Suite 500, Foster City, CA 94404 is the assignee of certain inventions as set forth in Exhibit H.

WHEREAS, Quercegen Pharma, AG., a corporation existing under the laws of Switzerland, having a business address at Buelstrasse 1, 8966 Oberwil, Likelihood, Switzerland, (hereinafter referred to as "ASSIGNEE"), is desirous of acquiring the entire right, title and interest in and to said PATENT PROPERTY and in and to any and all Letters Patent of the United States and foreign countries that have been or may be obtained therefor for said PATENT PROPERTY.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNORS, intending to be legally bound, has sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over to said ASSIGNEE, the entire right, title and interest in and to said PATENT PROPERTY and any and all continuations, divisions and renewals of and substitutes for said PATENT PROPERTY and to and under any and all additional Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and the full right to sue for and recover all profits and damages recoverable for past infringement of the same, and assign to and authorize said ASSIGNEE to

file applications for Letters Patent in all countries, to be held and enjoyed by said ASSIGNEE, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, sale and transfer not been made.

AND it is hereby covenanted that ASSIGNORS have full right to convey my entire interest herein assigned, and that ASSIGNORS have not executed and will not execute any agreement in conflict herewith, and ASSIGNORS further covenant and agree that it will each time a request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said PATENT PROPERTY in said ASSIGNEE, its successors, assigns, nominees, or legal representatives, and ASSIGNORS agree to communicate to said ASSIGNEE or to its nominee all known facts respecting said PATENT PROPERTY, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and to do everything possible to aid said ASSIGNEE, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said PATENT PROPERTY in any and all countries, all at the expense, however, of said ASSIGNEE, its successors, assigns, nominees, or legal representatives.


THE ASSIGNOR FURTHER WARRANTS AND COVENANTS that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned, and that the full right to convey the same as herein expressed is possessed by the undersigned.

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said ASSIGNEE, as assignee of the entire right, title and interest, any and all Letters Patent for said PATENT PROPERTY, including any and all Letters Patent of the United States which may be issued and granted on or as a result of any applications in said PATENT PROPERTY, in accordance with the terms of this ASSIGNMENT.




IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this ASSIGNMENT, hereunto sets their hand and seal on the 28th day of December, 2015.


Thomas Lines

By:   
Name: Thomas Lines


Quercegen Pharma LLC

By:   
Name: Thomas Lines

Quercegen Pharma LLP

By:   
Name: Thomas Lines


Quercegen Technologies

By:   
Name: Thomas Lines


Quercegen Pharmaceuticals, LLC

By:   
Name: Thomas Lines

Quercegen Holdings, LLC

By:   
Name: Thomas Lines

New Sun Nutrition, LLC

By:   
Name: Thomas Lines

The FRS Company

By:   
Name: Thomas Lines


**ACKNOWLEDGMENT**

STATE OF New York )  
COUNTY OF New York ) SS:

On this 28th day of December, 2015, before me, a Notary Public, the undersigned officer, personally appeared THOMAS LINES, to me known (or satisfactorily proven) to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

SEAL

Notary Public




My commission expires \_\_\_\_\_

GABRIELA STREET  
NOTARY PUBLIC - STATE OF NEW YORK  
NO. 01ST6304853  
Qualified in Queens County  
Certificate Filed in New York County  
My Commission Expires June 2, 2018

Quercegen Pharma AG.

By: 

Name: Thomas Lines 


**ACKNOWLEDGMENT**

STATE OF New York )  
COUNTY OF New York ) SS:

On this 28th day of December, 2015, before me, a Notary Public, the undersigned officer, personally appeared THOMAS LINES, to me known (or satisfactorily proven) to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

SEAL

Notary Public



My commission expires \_\_\_\_\_

GABRIELA STREET  
NOTARY PUBLIC - STATE OF NEW YORK  
NO. 01ST6304852  
Qualified in Queens County  
Certificate Filed in New York County  
My Commission Expires June 2, 2018



***Exhibit A- Patent Property***

All inventions, know-how, proprietary information, confidential information and any invention disclosures, patent applications and patents owned by Thomas Lines, whether existing under the laws of the United States or any other jurisdiction, including the patent applications and patents listed below and any and all continuations, divisions and renewals thereof and substitutes therefor and any foreign equivalents or counterparts thereof, and to and under any and all additional letters patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissues or extensions thereof.

### ***Exhibit B- Patent Property***

All inventions, know-how, proprietary information, confidential information and any invention disclosures, patent applications and patents owned by Quercegen Pharma LLC, whether existing under the laws of the United States or any other jurisdiction, including the patent applications and patents listed below and any and all continuations, divisions and renewals thereof and substitutes therefor and any foreign equivalents or counterparts thereof, and to and under any and all additional letters patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissues or extensions thereof.

- U.S. Application No. 11/778,237, filed 7/16/2007, entitled "Method for enhancing physical performance or immune system recovery from intense physical exercise with quercetin-containing compositions"
- U.S. Application No.12/212,947, filed 9/18/2008, entitled "Method for stabilizing quercetin"
- PCT/US2008/076795, filed 9/18/2008, entitled "Method for stabilizing quercetin"
- Canada, Application No. CA2700867, filed 9/18/2008, entitled "Use of vitamin b3 and vitamin c to stabilize quercetin in an aqueous solution"
- South Africa, Application No. ZA201002110, filed 9/18/2008, entitled "Method for stabilizing quercetin"
- Europe, Application No. EP08835871 filed 9/18/2008, entitled "Method for stabilizing quercetin"
- Russia, Application No. RU2010117350, filed 9/18/2008, entitled "Method for stabilizing quercetin"
- U.S. Provisional Application No. 60/839,579, filed 8/23/2006, entitled "Smallpox monoclonal antibody"
- U.S. Application No. 11/843,415, filed 8/22/2007, entitled "Smallpox monoclonal antibody"
- PCT/US2007/076532, filed 8/22/2007, entitled "Smallpox monoclonal antibody"
- Canada, Application No. CA2661659, filed 8/22/2007, entitled "Smallpox monoclonal antibody"
- Australia, Application No. AU2007342327, filed 8/22/2007, entitled "Smallpox monoclonal antibody"
- Taiwan, Application No. TW96131195, filed 8/22/2007, entitled "Smallpox monoclonal antibody"
- South Korea, Application No. KR20097005915, filed 8/22/2007, entitled "Smallpox monoclonal antibody"
- China, Application No. CN200780039448, filed 8/22/2007, entitled "Smallpox monoclonal antibody"
- South Africa, Application No. ZA200901481, filed 8/22/2007, entitled "Smallpox monoclonal antibody"
- Japan, Application No. JP2009525759, filed 8/22/2007, entitled "Smallpox monoclonal antibody"
- Europe, Application No. EP07872270, filed 8/22/2007, entitled "Smallpox monoclonal antibody"

***Exhibit C- Patent Property***

All inventions, know-how, proprietary information, confidential information and any invention disclosures, patent applications and patents owned by Quercegen Pharma LLP, whether existing under the laws of the United States or any other jurisdiction, including the patent applications and patents listed below and any and all continuations, divisions and renewals thereof and substitutes therefor and any foreign equivalents or counterparts thereof, and to and under any and all additional letters patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissues or extensions thereof.

***Exhibit D- Patent Property***

All inventions, know-how, proprietary information, confidential information and any invention disclosures, patent applications and patents owned by Quercegen Technologies, whether existing under the laws of the United States or any other jurisdiction, including the patent applications and patents listed below and any and all continuations, divisions and renewals thereof and substitutes therefor and any foreign equivalents or counterparts thereof, and to and under any and all additional letters patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissues or extensions thereof.

### ***Exhibit E- Patent Property***

All inventions, know-how, proprietary information, confidential information and any invention disclosures, patent applications and patents owned by Quercegen Pharmaceuticals, LLC, whether existing under the laws of the United States or any other jurisdiction, including the patent applications and patents listed below and any and all continuations, divisions and renewals thereof and substitutes therefor and any foreign equivalents or counterparts thereof, and to and under any and all additional letters patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissues or extensions thereof.

- U.S. Provisional Application No. 62/014,488, filed 6/19/2014, entitled "Method for treating cancer with a combination of quercetin and a chemotherapy agent"
- PCT/US2015/036618, filed 6/19/2015, entitled "Method for treating cancer with a combination of quercetin and a chemotherapy agent"
- U.S. Application No. 14/744,662, filed 6/19/2015, entitled "Method for treating cancer with a combination of quercetin and a chemotherapy agent"
- U.S. Provisional Application No. 61/021,937, filed 1/18/2008, entitled "Method for treating addiction using quercetin-containing compositions"
- PCT/US2009/031230, filed 1/16/2009, entitled "Method for treating addiction using quercetin-containing compositions"
- U.S. Application No. 12/355,208, filed 1/16/2009, entitled "Method for treating addiction using quercetin-containing compositions"
- Canada, Application No. CA2712195, filed 1/16/2009, entitled "Method for treating addiction using quercetin-containing compositions"
- Europe, Application No. EP09703059, filed 1/16/2009, entitled "Method for treating addiction using quercetin-containing compositions"
- U.S. Application No. 13/215,629, filed 8/23/2011, entitled "Method for treating addiction using quercetin-containing compositions"
- PCT/US2009/051511, filed 7/23/2009, entitled "Reducing cholesterol levels with combined use of quercetin and statin"
- Canada, Application No. CA2735826, filed 7/23/2009, entitled "Reducing cholesterol levels with combined use of quercetin and statin"
- U.S. Application No. 12/205,070, filed 9/5/2008, entitled "Reducing cholesterol levels with combined use of quercetin and statin"
- China, Application No. CN200980134939, filed 7/23/2009, entitled "Reducing cholesterol levels with combined use of quercetin and statin"
- India, Application No. IN2100/DELNP/2011, filed 7/23/2009, entitled "Reducing cholesterol levels with combined use of quercetin and statin"
- Europe, Application No. EP09811898, filed 7/23/2009, entitled "Reducing cholesterol levels with combined use of quercetin and statin"
- Russia, Application No. RU2011112936, filed 7/23/2009, entitled "Reducing cholesterol levels with combined use of quercetin and statin"
- U.S. Provisional Application No. 60/807,601, filed 7/17/2006, entitled "Quercetin-containing compositions"

- U.S. Provisional Application No. 60/807,694, filed 7/18/2006, entitled "Quercetin-containing compositions"
- U.S. Provisional Application No. 60/900,626, filed 2/8/2007, entitled "Quercetin-containing compositions"
- U.S. Provisional Application No. 90/911,747, filed 4/13/2007, entitled "Quercetin-containing compositions"
- U.S. Provisional Application No. 60/913,164, filed 4/20/2007, entitled "Quercetin-containing compositions"
- U.S. Application No. 11/778,234, filed 7/16/2007, entitled "Quercetin-containing compositions"
- PCT/US2007/073578, filed 7/16/2007, filed 7/16/2007, entitled "Quercetin-containing compositions"
- Taiwan, Application No. TW96125955, filed 7/16/2007, entitled "Quercetin-containing compositions"
- Europe, Application No. EP07799611, filed 7/16/2007, entitled "Quercetin-containing compositions"
- China, Application No. CN200780027405, filed 7/16/2007, entitled "Quercetin-containing compositions"
- Japan, Application No. JP2009520941, filed 7/16/2007, entitled "Quercetin-containing compositions"
- U.S. Application No. 12/639,212, filed 5/14/2009, entitled "Quercetin-containing compositions"
- PCT/US2007/073580, filed 7/16/2007, entitled "Quercetin-containing compositions"
- Taiwan, Application No. TW96125956, filed 7/17/2007, entitled "Quercetin-containing compositions"
- U.S. Application No. 12/821,287, filed 6/23/2010, entitled "Quercetin-containing compositions"
- U.S. Provisional Application No. 60/657,344, filed 2/28/2005, entitled "Composition for treating mental health disorders"
- PCT/ZA2006/000031, filed 2/28/2006, entitled "Composition for treating mental health disorders"
- U.S. Application No. 11/364,136, filed 2/27/2006, entitled "Composition for treating mental health disorders"
- Taiwan, Application No. TW95106573, filed 2/28/2006, entitled "Composition for treating mental health disorders"
- Europe, Application No. EP06740979, filed 2/28/2006, entitled "Composition for treating mental health disorders"
- U.S. Application No. 13/409,902, filed 3/1/2012, entitled "Composition for treating mental health disorders"
- Hong Kong, Application No. HK08105374, filed 2/28/2006, entitled "Composition for treating mental health disorders"
- U.S. Application No. 13/729,544, filed 12/28/2012, entitled "Method for treating metabolic syndrome and diabetes using quercetin and bauhinia forficata extract"
- U.S. Provisional Application No. 61/433,777, filed 1/18/2011, entitled "Flavonol compositions"

- U.S. Application No. 13/350,266, filed 1/13/2012, entitled "Flavonol compositions"
- PCT/US2012/021670, filed 1/18/2012, entitled "Flavonol compositions"
- Japan, Application No. JP2013550549, filed 1/18/2012, entitled "Flavonol compositions"
- Europe, Application No. EP12736678, filed 1/18/2012, entitled "Flavonol compositions"
- U.S. Application No. 13/303,467, filed 11/23/2011, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- Canada, Application No. CA2856506, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- PCT/US2012/066027, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- Australia, Application No. AU2012340840, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- Brazil, Application No. BR112014012610, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- South Korea, Application No. KR20147016393, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- Japan, Application No. JP2014543531, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- Mexico, Application No. MX2014006244, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- China, Application No. CN201280057722, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- India, Application No. IN999MUN2014, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- Russia, Application No. RU2014125062, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- Europe, Application No. EP12852154, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- South Africa, Application No. ZA201404494, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- Hong Kong, Application No. HK15109096, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- New Zealand, Application No. NZ62574612, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- Thailand, Application No. TH20141002826, filed 11/20/2012, entitled "Method for treating hepatitis c virus infection using quercetin-containing compositions"
- PCT/US2012/059341, filed 10/9/2012, entitled "Method for treating thrombotic disorders using quercetin-containing compositions"
- U.S. Application No. 13/272,508, filed 10/13/2011, entitled "Method for treating thrombotic disorders using quercetin-containing compositions"
- India, Application No. IN890MUN2014, filed 10/9/2012, entitled "Method for treating thrombotic disorders using quercetin-containing compositions"
- Europe, Application No. EP12840824, filed 10/9/2012, entitled "Method for treating thrombotic disorders using quercetin-containing compositions"

- Russia, Application No. RU2014118761, filed 10/9/2012, entitled “Method for treating thrombotic disorders using quercetin-containing compositions”
- China, Application No. CN201280050545, filed 10/9/2012, entitled “Method for treating thrombotic disorders using quercetin-containing compositions”
- PCT/US2009/049902, filed 7/8/2009, entitled “Improving renal function with quercetin-containing compositions”
- Canada, Application No. CA2730065, filed 7/8/2009, entitled “Improving renal function with quercetin-containing compositions”
- Australia, Application No. AU2009268637, filed 7/8/2009, entitled “Improving renal function with quercetin-containing compositions”
- U.S. Application No. 12/169,869, filed 7/9/2008, entitled “Improving renal function with quercetin-containing compositions”
- Europe, Application No. EP09795103, filed 7/8/2009, entitled “Improving renal function with quercetin-containing compositions”
- China, Application No. CN200980126978, filed 7/8/2009, entitled “Improving renal function with quercetin-containing compositions”
- New Zealand, Application No. NZ59076209, filed 7/8/2009, entitled “Improving renal function with quercetin-containing compositions”
- U.S. Application No. 14/224,686, filed 3/25/2014, entitled “Improving renal function with quercetin-containing compositions”
- Spain, Application No. ES09795103T, filed 7/8/2009, entitled “Improving renal function with quercetin-containing compositions”



### ***Exhibit F- Patent Property***

All inventions, know-how, proprietary information, confidential information and any invention disclosures, patent applications and patents owned by Quercegen Holdings, LLC, whether existing under the laws of the United States or any other jurisdiction, including the patent applications and patents listed below and any and all continuations, divisions and renewals thereof and substitutes therefor and any foreign equivalents or counterparts thereof, and to and under any and all additional letters patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissues or extensions thereof.

- PCT/US2003/33821, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Australia, Application No. AU2010202435, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Canada, Application No. CA2503373, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Australia, Application No. AU2003284919, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Germany, Application No. DE60336336, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- South Korea, Application No. KR20057007029, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Europe, Application No. EP03779239, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Austria, Application No. AT03779239T, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Denmark, Application No. DK03779239T, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Portugal, Application No. PT03779239T, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Spain, Application No. ES03779239T, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Japan, Application No. JP2004547143, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- Japan, Application No. JP2011052092, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- China, Application No. CN200380102103, filed 10/23/2003, entitled "Composition for enhancing exercise ability"
- Taiwan, Application No. TW92129416, filed 10/22/2003, entitled "Composition for enhancing physical performance"
- New Zealand, Application No. NZ540165, entitled "Composition for enhancing physical performance comprising quercetin, ascorbic acid and niacin"
- PCT/US2003/32552, filed 10/14/2003, entitled "Antioxidative Compositions"
- Europe, Application No. EP03774827, filed 10/14/2003, entitled "Antioxidative Compositions"

- Portugal, Application No. PT03774827T, filed 10/14/2003, entitled "Antioxidative Compositions"
- Denmark, Application No. DK03774827T, filed 10/14/2003, entitled "Antioxidative Compositions"
- Spain, Application No. ES03774827T, filed 10/14/2003, entitled "Antioxidative Compositions"
- Austria, Application No. AT03774827T, filed 10/14/2003, entitled "Antioxidative Compositions"
- Australia, Application No. AU2003282829, filed 10/14/2003, entitled "Antioxidative Compositions"
- Germany, Application No. DE60325265, filed 10/14/2003, entitled "Antioxidative Compositions"
- Hong Kong, Application No. HK06106781, filed 10/14/2003, entitled "Antioxidative Compositions"
- Korea, Application No. KR20057007030, filed 10/14/2003, entitled "Antioxidative Compositions"
- China, Application No. CN200380102104, filed 10/14/2003, entitled "Antioxidative Compositions"
- Canada, Application No. CA2503363, filed 10/14/2003, entitled "Antioxidative Compositions"
- Taiwan, Application No. TW92129007, filed 10/19/2003, entitled "Dietary Supplement"
- Japan, Application No. JP2004546861, filed 10/14/2003, entitled "Antioxidative Compositions"

***Exhibit G- Patent Property***

All inventions, know-how, proprietary information, confidential information and any invention disclosures, patent applications and patents owned by New Sun Nutrition, LLC, whether existing under the laws of the United States or any other jurisdiction, including the patent applications and patents listed below and any and all continuations, divisions and renewals thereof and substitutes therefor and any foreign equivalents or counterparts thereof, and to and under any and all additional letters patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissues or extensions thereof.

### ***Exhibit H- Patent Property***

All inventions, know-how, proprietary information, confidential information and any invention disclosures, patent applications and patents owned by The FRS Company, whether existing under the laws of the United States or any other jurisdiction, including the patent applications and patents listed below and any and all continuations, divisions and renewals thereof and substitutes therefor and any foreign equivalents or counterparts thereof, and to and under any and all additional letters patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissues or extensions thereof.

- U.S. Provisional Application No. 60/420,986, filed 10/23/2002, entitled "Antioxidative compositions"
- U.S. Application No. 10/302,544, filed 11/22/2002, entitled "Antioxidative compositions"
- U.S. Application No. 10/692,178, filed 10/23/2003, entitled "Composition for enhancing physical performance"
- U.S. Application No. 10/935,586, filed 9/7/2004, entitled "Antioxidative compositions"
- U.S. Application No. 11/124,433, filed 5/6/2005, entitled "Antioxidative compositions"
- U.S. Application No. 11/675,576, filed 2/15/2007, entitled "Composition for enhancing physical performance"
- U.S. Application No. 12/901,991, filed 10/11/2010, entitled "Composition for enhancing physical performance"
- U.S. Application No. 13/679,704, filed 11/16/2012, entitled "Composition for enhancing physical performance"